Background Atazanavir/ritonavir is as effective as lopinavir/ritonavir, with a more favourable
lipid profile and less gastrointestinal toxicity, in treatment-experienced HIV-1-infected patients…

Abstract Treatment of HIV-1-infected individuals with a combination of anti-retroviral agents
results in sustained suppression of HIV-1 replication, as evidenced by a reduction in plasma …

Background & Aims Interactions between CC chemokine receptor types 2 (CCR2) and 5 (CCR5)
and their ligands, including CCL2 and CCL5, mediate fibrogenesis by promoting …

Background: Once-daily atazanavir/ritonavir demonstrated similar antiviral efficacy to twice-daily
lopinavir/ritonavir over 48 weeks, with less gastrointestinal disturbance and a better …

Background: Long-term antiretroviral therapy, while dramatically reducing HIV-related
morbidity and mortality, is associated with metabolic and morphological changes. Peripheral fat …

Background: Abacavir/lamivudine and tenofovir/emtricitabine fixed-dose combinations are
commonly used first-line antiretroviral therapies, yet few studies have comprehensively …

Background. Human immunodeficiency virus (HIV)–infected individuals are at increased risk
of herpes zoster (HZ), even in the antiretroviral therapy (ART) era. Because concerns exist …

BackgroundCXCR4-using virus is associated with higher viral load and accelerated human
immunodeficiency virus (HIV) disease progression. Additionally, CCR5 antagonists may not …

Invasive pneumococcal infection is an important cause of morbidity and mortality in HIV-1-infected
individuals. B cells play an important role in maintaining serologic memory after …

OBJECTIVES: This article reviews the clinical manifestations of mitochondrial toxicity associated
with the use of nucleoside analog reverse transcriptase inhibitors (NRTIs) and outlines …